Technical Analysis for ARQL - ArQule, Inc.

Grade Last Price % Change Price Change
grade D 7.6716 -2.64% -0.21
ARQL closed up 0.7 percent on Friday, November 15, 2019, on 1.4 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Down
See historical ARQL trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion -2.64%
New Downtrend Bearish -1.96%
Shooting Star Candlestick Bearish -1.96%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.96%
Calm After Storm Range Contraction -1.96%
Narrow Range Bar Range Contraction -1.96%
Wide Bands Range Expansion -1.96%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.14%
Calm After Storm Range Contraction -1.14%
Narrow Range Bar Range Contraction -1.14%

Older signals for ARQL ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product candidate tivantinib is an inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase 3 clinical trial for the treatment of non-small cell lung and liver cancer; and Phase 2 clinical trial for the treatment of colorectal cancer. The company is also involved in the development of ARQ 087, an inhibitor of fibroblast growth factor receptor; ARQ 621, an inhibitor of the Eg5 kinesin motor protein; and ARQ 736, an inhibitor of the RAF kinases, which are in Phase 1 clinical development, as well as ARQ 761, an activator of the E2F-1 damage response/checkpoint pathway. It has partnership agreement with Daiichi Sankyo Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. for implementing a clinical development program designed to realize the broad potential of tivantinib as a single agent; and in combination with other anti-cancer therapies in various disease indications. In addition, the company has research collaboration with Daiichi Sankyo Co., Ltd. to discover selective inhibitors of two kinases in the field of oncology based on its ArQule Kinase Inhibitor Platform (AKIP) technology. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.
Chemistry Biotechnology Cancer Disease Organic Chemistry Cancer Therapies Colorectal Cancer Ethers Tyrosine Kinase Inhibitors Cancer Therapeutics Tyrosine Kinase Kinase Anti Cancer Therapies C Met Treatment Of Colorectal Cancer
Is ARQL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.22
52 Week Low 2.23
Average Volume 2,250,877
200-Day Moving Average 7.471
50-Day Moving Average 8.4061
20-Day Moving Average 8.878
10-Day Moving Average 8.173
Average True Range 0.5637
ADX 25.48
+DI 17.2606
-DI 32.7273
Chandelier Exit (Long, 3 ATRs ) 8.6589
Chandelier Exit (Short, 3 ATRs ) 8.6711
Upper Bollinger Band 10.7392
Lower Bollinger Band 7.0168
Percent B (%b) 0.23
BandWidth 41.928362
MACD Line -0.274
MACD Signal Line -0.0829
MACD Histogram -0.1911
Fundamentals Value
Market Cap 560.84 Million
Num Shares 71.2 Million
EPS -0.38
Price-to-Earnings (P/E) Ratio -20.74
Price-to-Sales 29.83
Price-to-Book 7.11
PEG Ratio -0.47
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.33
Resistance 3 (R3) 8.30 8.13 8.26
Resistance 2 (R2) 8.13 8.01 8.14 8.23
Resistance 1 (R1) 8.00 7.94 8.07 8.03 8.20
Pivot Point 7.83 7.83 7.86 7.84 7.83
Support 1 (S1) 7.70 7.71 7.77 7.73 7.56
Support 2 (S2) 7.53 7.64 7.54 7.53
Support 3 (S3) 7.40 7.53 7.51
Support 4 (S4) 7.43